Management and Outcomes of Type I and Type II Myocardial Infarction in Cardiogenic Shock

Area of Science:

• Cardiology
• Internal Medicine
• Critical Care Medicine

Background:

• Type I myocardial infarction (T1MI) and Type II myocardial infarction (T2MI) have distinct underlying etiologies.
• The clinical outcomes of T1MI versus T2MI in patients experiencing cardiogenic shock (CS) remain poorly understood.
• This study aimed to elucidate differences in clinical features, biomarkers, and outcomes between T1MI-CS and T2MI-CS subgroups.

Purpose of the Study:

• To compare clinical characteristics, cardiac biomarker profiles, and clinical outcomes between patients with T1MI-CS and T2MI-CS.
• To identify predictors associated with T2MI in the context of cardiogenic shock.

Main Methods:

• Analysis of 103 patients with acute myocardial infarction-associated CS from the CAPITAL-DOREMI trial.
• Patients were categorized into T1MI (n=61) or T2MI (n=42) groups.
• The primary endpoint was a composite of 30-day all-cause in-hospital mortality, cardiac arrest, need for mechanical circulatory support, or renal replacement therapy.

Main Results:

• No significant difference in the primary composite endpoint was observed between T1MI-CS and T2MI-CS groups (aHR, 1.63; 95% CI, 0.96-2.77; P=0.07).
• Patients with T1MI-CS exhibited significantly elevated troponin I and creatine kinase levels compared to T2MI-CS.
• T1MI-CS patients presented with decreased urine output; predictors of T2MI-CS included nonischemic ventricular dysfunction, atrial fibrillation, and COPD.

Conclusions:

• Despite differing biomarker profiles and clinical presentations, no significant differences in adverse clinical outcomes were found between T1MI-CS and T2MI-CS.
• Numerically higher adverse events were observed in T1MI-CS, though the small sample size limits definitive conclusions.
• This study generates hypotheses regarding the clinical and biochemical distinctions between T1MI and T2MI in cardiogenic shock.